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Abstract
Background: In Australia, clinical guidelines for primary prevention of cardiovascular disease recommend the use of the
Framingham model to help identify those at high risk of developing the disease. However, this model has not been
validated for the Indigenous population.
Design: Cohort study.
Methods: Framingham models were applied to the Well Person’s Health Check (WPHC) cohort (followed 1998–2014),
which included 1448 Aboriginal and Torres Strait Islanders from remote Indigenous communities in Far North
Queensland. Cardiovascular disease risk predicted by the original and recalibrated Framingham models were compared
with the observed risk in the WPHC cohort.
Results: The observed five- and 10-year cardiovascular disease probability of the WPHC cohort was 10.0% (95%
confidence interval (CI): 8.5–11.7) and 18.7% (95% CI: 16.7–21.0), respectively. The Framingham models significantly
underestimated the cardiovascular disease risk for this cohort by around one-third, with a five-year cardiovascular
disease risk estimate of 6.8% (95% CI: 6.4–7.2) and 10-year risk estimates of 12.0% (95% CI: 11.4–12.6) and 14.2%
(95% CI: 13.5–14.8). The original Framingham models showed good discrimination ability (C-statistic of 0.67) but a
significant lack of calibration (2 between 82.56 and 134.67). After recalibration the 2008 Framingham model corrected
the underestimation and improved the calibration for five-year risk prediction (2 of 18.48).
Conclusions: The original Framingham models significantly underestimate the absolute cardiovascular disease risk for
this Australian Indigenous population. The recalibrated 2008 Framingham model shows good performance on predicting
five-year cardiovascular disease risk in this population and was used to calculate the first risk chart based on empirical
validation using long-term follow-up data from a remote Australian Indigenous population.
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Introduction
Indigenous Australians have substantially poorer
health outcomes and have a life expectancy of approxi-
mately 10 years lower than that of the non-Indigenous
population.1 In this population, cardiovascular disease
(CVD) is the leading cause of death, with an age-
adjusted death rate 1.3 times higher than that of
non-Indigenous Australians.2 In Australia, clinical
guidelines for primary prevention of CVD recommend
the 1991 Framingham CVD model3 as an important
component of guidelines used to identify those at high
risk of developing CVD over a five-year period.4
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The development of CVD risk prediction models using
Framingham study data dates back to the late 1960s.5,6
The most widely used model was developed by
Anderson and colleagues to predict the risk of develop-
ing CVD and its component diseases (coronary heart
disease (CHD), myocardial infarction and stroke) for
people aged 30–75 years.3 In 2008 an updated sex-spe-
cific Framingham model was published to predict 10-
year CVD risks.7
The Framingham CVD models have been validated
and recalibrated in various countries and ethnicities8–10
as well as in the Australian general population.11,12
However, it has not been validated or recalibrated for
an Australian Indigenous population. One previous
study (2005) compared the predicted and observed
CHD rates in an Australian Aboriginal remote commu-
nity sample and found that the 1991 Framingham
model substantially underestimated CHD rates across
all age groups and both sexes.13 In the current
Australian CVD management guidelines, people with
the following characteristics are automatically put
into the high risk category: diabetes and aged over 60
years, diabetes with microalbuminuria, estimated glom-
erular filtration rate< 45ml/min per 1.73m2, familial
hypercholesterolemia, high blood pressure and serum
total cholesterol> 7.5mmol/l, and any Aboriginal or
Torres Strait Islander over the age of 74 years.4
However, the developers of these guidelines acknow-
ledge that there is little empirical evidence supporting
this classification system (a combination of level D
weak evidence plus a consensus-based recommenda-
tion).4 Further, for Aboriginal and Torres Strait
Islander adults aged between 35 and 74 years who are
not in this clinically determined high risk category, the
guidelines recommend the use of the 1991 Framingham
CVD model to estimate five-year absolute CVD risks
while acknowledging that it might result in an under-
estimation of these risks.4
In this study, we validated both the 1991 and 2008
Framingham CVD models using a cohort of Aboriginal
and Torres Strait Islander adults drawn from remote
Indigenous communities in Far North Queensland.
Recalibration was also conducted to help generate
more accurate CVD risk predictions for this popula-
tion. Finally, we developed a CVD risk chart that
could help improve the assessment and management
of CVD in the Australian Indigenous population, par-
ticularly those in remote regions of Australia.
Methods
Participants
The source population of the present study were
obtained from the Well Person’s Health Check
(WPHC), which was conducted between 1998 and
2000 and consisted of 3508 people in 26 remote
Indigenous communities in Far North Queensland.14
The study was approved by the Cairns Institutional
Health Ethics Committee with support from
Apunipima Cape York Health Council (HREC/
141QCH/121-936). Participation in the WPHC study
was open to all people residing in these communities
and involved a broad range of recruitment strategies
including printed media and local radio as well as
through health services and community groups.14
Information collected in the WPHC survey can be
found in the Supplementary Material online. Baseline
data of the participants were linked to hospitalization
and death records in the Queensland Hospital
Admitted Patient Data Collection dataset from the ini-
tial screening date to the end of 2014, using linkage
software applying deterministic and probabilistic meth-
odologies, as well as manual clerical reviews where
required. For our study, we included 1684 (98.8%)
people aged between 30 and 74 years who have a
unique link to their hospitalization and death records.
We excluded people with previous CVD events
(n¼ 101) or whose baseline characteristics were missing
(n¼ 135).
Baseline risk factors were collected from the WPHC
screening data, including systolic blood pressure, total
cholesterol level, high-density lipoprotein (HDL) chol-
esterol level, fasting glucose level and smoking status.
Details of the methods used to collect these indicators
have been published elsewhere.14 People with diabetes
were identified if they self-reported (confirmed through
medical record check) or had a baseline fasting
glucose> 7.8mmol/l.
One hundred and forty (8.3%) people had one or
more baseline risk factors missing (six with missing
systolic blood pressure value; 49 with missing total
cholesterol and 134 with missing HDL cholesterol),
which were excluded from the main analysis.
Sensitivity analysis was conducted where we replaced
the missing values with estimated values from multiple
imputation by chained equations on five occasions and
used standard statistical rules to produce reported
results.15 Electrocardiogram–left ventricular hypertro-
phy (ECG-LVH; required for the 1991 Framingham
model) and hypertension treatment (required for the
2008 Framingham model) were not collected during
WPHC screening. We presumed these values to be the
average of the Framingham population and used hypo-
thetical values in the sensitivity analysis.
Outcomes
CVD events were identified using the International
Classification of Disease diagnosis and procedure
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codes (version 9 and 10; see Supplementary Material)
for the following outcomes in hospitalization and death
records: CHD (including myocardial infarction, angina
pectoris and coronary insufficiency), CHD death,
stroke, congestive heart failure and peripheral vascular
disease as defined by Anderson et al. in the
Framingham study.3
The start date of follow-up was the screening date of
the WPHC and the censor date was the date of first
CVD event or death, whichever came first, or otherwise
the date of last known admission. If neither admission
nor death occurred during follow-up, the censor date
was 1 December 2014, which was the last known admis-
sion date of the study.
Statistical analysis
We used three models to predict five-year and 10-year
CVD risks in our study cohort. The first two were
the original 1991 and 2008 Framingham models.3,7
As only the 10-year baseline survival rate was
reported in the 2008 Framingham model, this model
predicted 10-year CVD risk only. The third model
was a recalibrated 2008 Framingham equation, in
which both the baseline five-year and 10-year survival
rates and mean values of the risk factors were esti-
mated using the WPHC sample and coefficients on
risk factors were obtained from the original 2008
Framingham model. In detail, the 2008
Framingham model (Cox equation) is:
P ¼ 1 S0ðtÞexpðbiXibiMiÞ
where bi represents the regression coefficients, Xi rep-
resents an individual’s risk factors, Mi represents the
means of the risk factors of the Framingham cohort,
S0(t) represents the Framingham baseline CVD rate at
year 10. To recalibrate this Framingham equation, we
replaced the Framingham means of the risk factors
(Mi) with the means in our own cohort, while the
Framingham baseline CVD rate S0(t) was replaced
with the cohort’s baseline five-year or 10-year CVD
rate. The coefficients were kept the same as in the
Framingham model (Table A in Supplementary
Material).
Age- and sex-specific predicted five-year (original
1991 and recalibrated 2008 models) and 10-year
(all three models) CVD risks for people aged
between 30 and 74 years were calculated and com-
pared with the observed CVD probabilities (estimated
using the Kaplan–Meier method). The 95% confi-
dence intervals of the differences between the pre-
dicted and observed probabilities were estimated
using the bootstrap method with 1000 bootstrapped
replications.
Discrimination
Discrimination refers to the ability of a prediction
model to correctly distinguish those who will develop
an event from those who will not. We quantified this by
calculating Harrell’s C-statistic,16 which represents the
probability of concordance amongst all pairs of subjects
in which at least one had an event. Concordance refers
to two subjects’ predicted probabilities of survival and
survival times going in the same direction, for example,
the person who has higher predicted probability of sur-
vival also survives longer in reality.
Calibration
Calibration describes how closely the predicted prob-
abilities agree with observed outcomes. We used two 2
statistics to evaluate calibration. The first method was
proposed by D’Agostino and Nam,17 which compared
the predicted and observed probabilities by deciles
based on the predicted risk. Plots were constructed
showing predicted and actual probabilities of CVD
events in each decile. A 2 statistic exceeding 20 was
used to indicate a significant lack of calibration
(p< 0.01).8 The second method used the 2 statistics
with cross-classified categories proposed by Cook,18
in which a reclassification table was built to divide par-
ticipants into different risk categories based on predic-
tions from both original and recalibrated Framingham
models. The observed and predicted probabilities were
compared for all cells with at least 20 individuals.18
To investigate the validity of the recalibrated model,
the repeat data-splitting (cross validation) method was
used for internal validation. The original sample was
randomly divided into five samples; the recalibration
was conducted on all sets of four of these samples,
and the resulting five recalibrated models were used
to estimate the risk in the fifth omitted sample (i.e.
those individuals not used in the model development).
The C-statistic and Nam–D’Agostino 2 were
computed on the estimated results. This data-splitting
procedure was repeated 200 times to obtain stable
results.
All statistical analyses were performed in Stata ver-
sion 13.1(StataCorp LP, College Station, TX, USA).
CVD risk chart
A five-year CVD risk chart for the Australian
Indigenous population was generated based on the
recalibrated 2008 Framingham model. To keep the
chart simple and comparable to the existing
Australian CVD charts19 we retained stratification by
the total cholesterol:HDL ratio. This was achieved
by fixing HDL at 1.2mmol/l, the average level in
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this sample. We varied the HDL level by 0.6mmol/l
(covering the maximal values of HDL in the study
cohort) to test its effect on the predicted risk levels in
a sensitivity analysis.
Results
The study cohort consisted of 1448 people from the
WPHC cohort (see flowchart in the Supplementary
Material). Baseline risk factors of this cohort are pro-
vided in Table 1. Compared with the cohort used to
estimate the 2008 Framingham model7 our study
cohort is slightly younger and has a higher proportion
of smokers and diabetes patients at baseline. The 10-
year baseline survival rates in the study cohort are
much lower compared with the Framingham cohort
(Table 1).
The 1448 people contributed 15,221 person-years of
follow-up in total, with a mean and maximal follow-up
time of 10.5 and 16.4 years, respectively. During the
follow-up 369 (25.5%) people developed at least one
CVD event. The five- and 10-year probabilities of
CVD events were 10.0% (95% confidence interval
(CI): 8.5–11.7) and 18.7% (95% CI: 16.7–21.0), respect-
ively (Table 2).
The overall predicted five-year CVD risk using the
1991 Framingham model was 6.8% (95% CI: 6.4–7.2).
The predicted 10-year risk was 14.2% (95% CI: 13.5–
14.8) and 12.0% (95% CI: 11.4–12.6) using the 1991
and 2008 Framingham models, respectively. All predic-
tions significantly underestimated the observed CVD
probabilities in the WPHC cohort by around one-
third, with differences being 3.2% (95% CI: 1.9–4.5)
for five-year risk and 4.5% (95% CI: 2.9–6.3) to
6.7% (95% CI: 5.0–8.5) for 10-year risk. Sensitivity
analyses which estimated predicted risk by adjusting
the prevalence of ECG-LVH or hypertension produced
similar results and are reported in the Supplementary
Material.
After baseline risk recalibration, five-year total and
age- and sex-specific predicted risks were similar to the
observed results (Table 2). The predicted 10-year prob-
ability of CVD events using the recalibrated model was
higher than the observed risk, mainly because of over-
estimation in the 55–74 year age group (Table 2).
Compared with the predictions from the original 1991
Framingham model, after recalibration 165/1096
people in the low five-year CVD risk (<10%) category
and 146/186 people in the moderated five-year CVD
risk (10%–15%) category moved to a higher risk cat-
egory; the predicted number of people with high five-
year CVD risk (>15%) almost doubled, from 166 to
322, in the cohort (p< 0.001). The probabilities of CVD
events using the imputed data were similar and are
reported in the Supplementary Material.
Table 3 contains the C-statistics and 2 estimates for
different models. The C-statistics were between 0.668
and 0.674, with no significant differences. We found a
significant lack of calibration (p< 0.001) for the ori-
ginal (five- and 10-year) and recalibrated (10-year)
Framingham risk estimations. The recalibrated five-
year risk prediction showed improvement on calibra-
tion (Nam–D’Agostino 2¼ 18.48, p¼ 0.03, Cook
2¼ 11.82, p¼ 0.07). Figure 1 compares predicted
risks using the 2008 Framingham model and actual
risks of CVD events for each decile of predicted risk.
The original model (Figure 1(a)) shows poor calibra-
tion between estimated and observed risk in all deciles,
except for the last decile. This was greatly improved
after recalibration (Figure 1(b) and (c)); however, for
Table 1. Baseline risk factors and survival rates for people 30–75 years old in the Framingham7 and WPHC Indigenous cohort.
Framinghama WPHC cohort (30–75)b
Risk factors
Women
n¼ 4522
Men
n¼ 3969
Women
n¼ 748
Men
n¼ 700
Age, mean (SD), years 49.1 (11.1) 48.5 (10.8) 45.2 (11.6) 44.9 (11.0)
Total-C, mean (SD), mmol/l 5.6 (1.1) 5.5 (1.0) 5.0 (1.0) 5.3 (1.1)
HDL-C, mean (SD), mmol/l 1.5 (0.4) 1.2 (0.3) 1.1 (0.3) 1.2 (0.3)
Systolic BP, mean (SD), mmHg 125.8 (20.0) 129.7 (17.6) 133.0 (21.7) 136.8 (17.9)
Smoking, n (%) 1548 (34.2) 1398 (35.2) 352 (47.1) 442 (63.1)
Diabetes, n (%) 170 (3.8) 258 (6.5) 187 (25.0) 134 (19.1)
Baseline five-year survival rate N/A N/A 0.931 0.916
Baseline 10-year survival rate 0.950 0.889 0.846 0.811
aAdapted from data in D’Agostino.7
bThe WPHC values were used for recalibration of the 2008 Framingham model.
WPHC: Well Person’s Health Check; SD: standard deviation; Total-C: total cholesterol; HDL-C: high-density lipoprotein cholesterol; BP: blood
pressure; N/A: not applicable
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the recalibrated 10-year risk large differences are still
evident between the estimated and observed risks in
the last decile. The performance of the recalibrated
model on five-year risk prediction did not change
after internal validation, with a C-statistic of 0.678
(95% CI: 0.616–0.728) and Nam–D’Agostino 2 of
14.4 (95% CI: 10.0–20.9).
Based on the recalibrated 2008 Framingham model,
a five-year absolute CVD risk chart was built for the
Australian Indigenous population (Figure 2).
Predictions for people aged between 30 and 34 years
were included because of the high CVD risk levels for
certain populations in this age range (e.g. smokers with
diabetes). A sensitivity analysis (reported in the
Supplementary Material) showed that varying HDL
levels by 0.6mmol/l produced only a small change
of risk scores that would have a minimal impact on
the classification of standard risk charts.
Discussion
The 1991 and 2008 Framingham CVD models substan-
tially underestimated the absolute CVD risk in the
Australian Indigenous cohort used in our study. Both
models showed a lack of calibration to the observed
CVD probabilities. Using the baseline risk from our
study population we recalibrated the five-year CVD
risk to a level considered acceptable by the developers
of the Framingham model.8 The recalibrated equation
was used to calculate the first CVD risk chart based on
empirical validation using long-term follow-up data
from an Indigenous Australian population.
The high CVD risk among Indigenous people pre-
sented in this study is not unique in Australia. The
Strong Heart Study found that CHD rates in
American Indians exceed rates in other US popula-
tions and may more often be fatal.20 A study in
Canada found that Aboriginal people had a signifi-
cantly higher frequency of CVD compared with
Europeans (18.5% vs. 7.6%).21 Although a variety
of CVD risk models are available, few have been
based on or calibrated using Indigenous-specific
observed data. In the Strong Heart Study, both reca-
libration of the Framingham model and development
of a specific risk equation for the American Indians
have been conducted to help better stratify the CHD
Table 2. Five-year and 10-year probability of CVD events in the WPHC Indigenous sample, observed and predicted probabilities
using three different Framingham models.
Sample
size n
Observed probability
% (95% CI)
Predicted probability % (95% CI)
Framingham 1991 Framingham 2008
Recalibrated
Framingham 2008
Five-year risk
Total 1448 10.0 (8.5–11.7) 6.8 (6.4–7.2) N/Aa 10.4 (9.9–10.9)
Gender
Female 748 9.2 (7.3–11.6) 5.7 (5.2–6.2) N/Aa 9.6 (8.9–10.3)
Male 700 10.8 (8.7–13.4) 8.0 (7.4–8.5) N/Aa 11.3 (10.5–12.1)
Age group, years
30–34 301 3.5 (1.9–6.5) 1.3 (1.2–1.5) N/Aa 2.8 (2.6–3.1)
35–44 486 3.9 (2.5–6.2) 3.8 (3.4–4.1) N/Aa 6.2 (5.8–6.6)
45–54 354 13.5 (10.3–17.6) 8.0 (7.5–8.6) N/Aa 11.9 (11.1–12.7)
55–74 307 21.7 (17.4–26.8) 15.5 (14.5–16.5) N/Aa 22.7 (21.2–24.2)
Ten-year risk
Total 1448 18.7 (16.7–21.0) 14.2 (13.5–14.8) 12.0 (11.4–12.6) 21.2 (20.3–22.1)
Gender
Female 748 17.3 (14.7–20.5) 12.2 (11.3–13.0) 8.9 (8.2–9.5) 19.6 (18.3–20.8)
Male 700 20.2 (17.2–23.6) 16.3 (15.3–17.3) 15.4 (14.3–16.4) 22.9 (21.5–24.3)
Age group, years
30–34 301 8.1 (5.4–12.2) 3.5 (3.2–3.9) 3.3 (3.0–3.6) 6.5 (6.0–7.0)
35–44 486 12.0 (9.2–15.5) 8.9 (8.3–9.5) 7.3 (6.8–7.8) 13.7 (12.8–14.5)
45–54 354 24.5 (20.1–29.6) 17.2 (16.2–18.2) 14.1 (13.1–15.1) 25.0 (23.6–26.5)
55–74 307 32.8 (27.6–38.7) 29.5 (28.0–31.0) 25.6 (23.9–27.4) 43.1 (40.9–45.3)
aThe baseline five-year survival rate was not reported in the D’Agostino 2008 study. Therefore, we were unable to calculate five-year risk using the
original Framingham 2008 model.
CVD: cardiovascular disease; WPHC: Well Person’s Health Check; CI: confidence interval; N/A: not applicable
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risk in this population.8,22 As far as we are aware
there is no similar study for Indigenous Australians.
So, instead of trying more CVD risk models which
were built based on other populations, we feel it is
important to generate/recalibrate a prediction tool
based on Indigenous Australian data. We hope this
study represents a first step to producing a more
accurate estimate of CVD risk for Indigenous
Australians.
Implications
There is an important practical application of this
research, as a previous study on CVD risk identifica-
tion and management in Indigenous Australians
showed that more than half of this population were
not screened for CVD as recommended in national
guidelines for cardiovascular risk management.23
Current guidelines for remote health services in
Table 3. Performance of the original and recalibrated Framingham models in predicting five-year and 10-year CVD events.
Original Framingham
Recalibrated
Framingham 20081991 2008
Five-year risk
Discrimination
C 0.671 N/Aa 0.674
95% CI of C (0.643–0.699) N/Aa (0.646–0.702)
Calibration
Nam–D’Agostino 2 (DF 9) 85.44 N/Aa 18.48
p value for Nam–D’Agostino 2 <0.001*** N/Aa 0.03*
Cook 2 (DF 6) 43.84 N/Aa 11.82
p value for Cook 2 <0.001*** N/Aa 0.07
Ten-year risk
Discrimination
C 0.671 0.668 0.674
95% CI of C (0.643–0.699) (0.640–0.696) (0.646–0.702)
Calibration
Nam–D’Agostino 2 (DF 9) 82.56 134.67 51.09
p value for Nam–D’Agostino 2 <0.001*** <0.001*** <0.001***
Cook 2 (DF 6) 65.91 116.13 34.65
p value for Cook 2 <0.001*** <0.001*** <0.001***
aThe baseline five-year survival rate was not reported in the D’Agostino 2008 study. Therefore, we were unable to calculate five-year risk using the
original Framingham 2008 model. *P< 0.05 ***P< 0.001
CI: confidence interval; C: C-statistics; DF: degree of freedom; N/A: not applicable
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Figure 1. Calibration by decile for cardiovascular disease (CVD) risk of the original and recalibrated 2008 Framingham model.
Horizontal-axes refer to decile of predicted risk based on the 2008 Framingham CVD model; vertical-axes refer to observed and
model-based predicted probabilities of CVD event. (a) Original model (10-year risk), (b) Recalibrated model (five-year risk) and
(c) Recalibrated model (10-year risk).
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Indigenous communities use a CVD Risk Assessment
tool which is an adaptation of the general Australian
CVD charts based on the 1991 Framingham model,19
with a 5% upwards adjustment and additional esti-
mates for a younger cohort aged 20–44 years.24 In
this study we provide a risk chart derived from the
recalibrated Framingham model based on the actual
risk observed in a remote Indigenous population and
so provide evidence that enables prediction of risk to
be refined.
The more accurate calculation of CVD risk will
enable better identification for Indigenous Australians
in primary prevention. However, the assessment of
CVD risk is just one component of a wide range of
strategies to improve Indigenous health and thereby
achieve the Council of Australian Governments’
target on closing the gap in life expectancy.25 To
tackle the large numbers of high CVD risk patients
more resources are required. This will need co-ordina-
tion with a range of primary care and allied health
practitioners. Key to this will be the development of
early risk intervention teams as well as broader
community strategies such as improving infrastructure
to promote healthy behaviours in Indigenous
communities.
Future studies
After baseline calibration, there was no significant dif-
ference between the predicted and the observed five-
year CVD risks. However, overestimation occurred
when using the recalibrated 10-year prediction model,
mainly because of overestimation in the older age
group. Hence we produced five-year absolute CVD
risk charts only. Unlike most guidelines in other coun-
tries that dictate therapeutic intervention strategies be
based on 10-year CVD risk predictions,26 currently
Australian guidelines for primary prevention of cardio-
vascular disease are based on five-year CVD risk pre-
dictions. We believe the five-year risk charts produced
in this study can provide a reference to identify
Indigenous Australians with high CVD risk.
However, future research should focus on generating
more accurate predictions for 10-year CVD risk,
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Figure 2. Five-year cardiovascular risk charts based on the recalibrated Framingham model.
This chart is based on 2008 Framingham model that has been recalibrated using information on Aboriginal and Torres Strait Islander
participants from the Well Persons Health Check study, which recruited people from 26 remote communities from Far North
Queensland. It has not been validated for use in other Indigenous populations.
For people under treatment for high blood pressure, 5% should be added to the risk on the chart.
HDL: high-density lipoprotein
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so clinical decisions can be made based on both short-
term and long-term risk predictions.
According to the data released by the Australian
Bureau of Statistics, it was estimated that in 2011
there were 669,900 Indigenous people in Australia,
accounting for 3% of the total Australian population;
the largest population of Indigenous Australians lived
in New South Wales (31.1%) and Queensland (28.2%);
34.8% of all Indigenous Australians lived in major
cities of Australia, 43.8% people lived in inner or
outer regional Australia and 21.4% lived in remote
Australia.27 Based on the Australian Aboriginal and
Torres Strait Islander Health Survey in 2013, there
was no significant difference in various health condi-
tions and risk factors for Indigenous people across dif-
ferent states/territories in Australia.28 While the present
study used a cohort from North Queensland, our
results are consistent with a previous study that used
an Indigenous cohort from remote regions of central
Australia and also showed that the Framingham
model underestimated CHD rates.13 Currently there is
no corresponding study available on the CVD risk of
Indigenous Australians in non-remote areas and so fur-
ther external validation of our recalibrated model is
required to determine the clinical utility of these risk
charts in other Indigenous populations.
After adjustment of the baseline risk of the
Framingham model in this study, calibration of the
model largely improved but discrimination had no sig-
nificant change. Previous studies have shown that other
risk factors, such as urinary albumin creatinine ratio,
waist circumference and triglycerides, also contributed
to the development of CVD in a population with a high
prevalence of diabetes.22,29,30 Social determinants such
as education have also been reported as relevant to
CVD risks.31,32 Another possible risk factor is rheum-
atic heart disease, which can increase the risk for cer-
tain types of CVD (heart failure and stroke) and has
high prevalence and mortality rate among Australian
Indigenous people.33,34 This suggests that further reca-
libration which includes other predictors of CVD risk
or the development of a new model specifically for the
Australian Indigenous population which incorporates
these risk factors should be a research priority. It
would also be interesting to look at the population
attributed risk for each of the traditional and new
risk factors in the Indigenous population, which
would provide evidence to promote more targeted stra-
tegies to reduce CVD risks.
Strengths and limitations
Strengths of the present study include the use of a rela-
tively large baseline sample, long follow-up and object-
ive measures (rather than self-reported) of baseline risk
factors. There are also some limitations of our study.
The participants of this study were from remote
Indigenous communities in Far North Queensland who
volunteered to participate in a population screening pro-
gram. The mode of recruitment may have influenced the
representativeness of the sample, which would impact on
generalizability if other factors not contained in the
Framingham models influence risk (e.g. body mass
index) and differ between the sample and the population.
External validation on our recalibrated Framingham
model should be conducted in future studies involving
other Indigenous populations (e.g. Indigenous
Australians living in urban areas). Second, parametric
uncertainty was not considered in this study when com-
paring observed and predicted CVD probabilities, as no
variance–covariance matrices were reported for the ori-
ginal Framingham CVD models.35
Conclusion
In conclusion, we found that both the 1991 and 2008
Framingham model underestimated the CVD risk in
the Australian Indigenous population by about one-
third on average. A recalibrated equation was used to
calculate the first risk chart based on empirical valid-
ation using long-term follow-up data from remote
Indigenous communities in Far North Queensland.
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